News

FDA says knockoff versions of Lilly obesity drug must come off the market

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next year under a federal decision issued Thursday. The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become wildly popular with Americans trying to lose weight. The decision is a win for Lilly — which had been pressing the FDA to take the step for months — and is expected to impact how patients access the drugs, including how much they pay.

Oil Falls After Federal Reserve Outlook Boosts US Dollar

(Bloomberg) -- Oil fell by almost 1% to settle below $70 a barrel as expectations for fewer interest-rate cuts by the US Federal Reserve boosted the dollar.Most Read from BloombergNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets as Saharan Dust Descends on SenegalFed officials lowered borrowing costs as expected on Wednesday, but reined in the number of reductions they expect to ma

Mexico Delivers Fourth Straight Rate Cut as Inflation Slows

(Bloomberg) -- Mexico cut interest rates for a fourth straight meeting Thursday as inflation is slowing back to target and the economy is losing momentum. Most Read from BloombergNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets as Saharan Dust Descends on SenegalBanxico, as the central bank is known, lowered borrowing costs by a quarter-point to 10% in an unanimous decision. The mo

Office Rebound Expected in 2025 While Other Real Estate Stocks to See Trouble

(Bloomberg) -- It’s been a challenging couple of years for real estate stocks since the Federal Reserve started raising interest rates in 2022, as borrowing costs soared and the property market collapsed. And despite a healthy rebound in the middle of 2024, the outlook for 2025 isn’t particularly encouraging.Most Read from BloombergNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets a